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Abstract
Rationale Treatment of the most widely abused drugs,
nicotine and alcohol, is hampered by high rates of relapse.
Varenicline tartrate, an α4β2 nicotinic receptor partial
agonist, is currently prescribed as a smoking cessation aid.
However, there is emerging evidence that it may also
modulate alcohol seeking and cognitive functioning in rats.
Objectives As preclinical data on alcohol taking and relapse
are limited, we used a self-administration–reinstatement
model to evaluate the effects of varenicline on operant
responding for alcohol (12%, v/v), intravenous nicotine
(40 μg/kg/inf.), sucrose (10%, w/v) and on cue-induced
relapse to alcohol and nicotine seeking in rats. At the
serial reaction time task (5-CSRTT) performance with a
focus on correct responses (attention) and premature
responding (impulsivity), modalities that have previously
been associated with addictive behaviour.
Results Varenicline, at doses of 1.5 and 2.5 mg/kg, reduced
alcohol and nicotine self-administration and enhanced
operant responding for sucrose. At these doses, varenicline
reduced cue-induced relapse to alcohol, but not nicotine
seeking. In contrast, at 0.5 mg/kg, varenicline facilitated
cue-induced nicotine seeking. Similar to nicotine, vareni-
cline increased premature responding at low doses, but had
no effect on any of the other behavioural parameters in the
5-CSRTT.
Conclusions Our data indicate that varenicline specifically
reduced responding for nicotine and alcohol, but not for
natural reinforcers such as sucrose. Interestingly, vareni-
cline strongly attenuated cue-induced relapse to alcohol
seeking, but not nicotine seeking. Varenicline may therefore
be a promising aid in the treatment of alcohol addiction.
Keywords Varenicline.Self-administration.Relapse.
5-CSRTT.Nicotine.Alcohol
Introduction
Alcohol and nicotine are the two most widely abused
addictive substances. While several pharmacological treat-
ments for alcohol and nicotine dependence are targeted at
reducing drug intake, these treatments generally demon-
strate limited protection against relapse (Anton et al. 2006;
Frishman 2009). In this respect, varenicline, a novel agent
currently prescribed to aid smoking cessation, may have a
more favourable pharmacological profile than other regis-
tered pharmacotherapeuticals, such as bupropion (Gonzales
et al. 2006; Jorenby et al. 2006). Varenicline is a partial
α4β2 nicotinic receptor agonist and was developed with
the assumption that such agents may possibly diminish the
consequences of both nicotine exposure and its absence.
Partial α4β2 nicotinic receptor agonists are postulated to
promote smoking cessation by preventing nicotine from
binding to the receptor. At the same time, by partial
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cognitive level, we assed varenicline's effects on 5-choiceactivation of α4β2 nicotinic receptors, such agents would
moderately increase mesolimbic dopamine release, which is
believed to alleviate craving (Coe et al. 2005; Niaura et al.
2006). Indeed, clinical observations indicate that vareni-
cline is able to (1) reduce withdrawal symptoms and
negative affect during abstinence in treatment-seeking
smokers, (2) attenuate the subjective rewarding effects of
nicotine during a scheduled smoking lapse and (3) increase
the number of abstinent days following the smoking lapse
in a subgroup of participants (Patterson et al. 2009).
Consistent with these clinical findings, preclinical evidence
confirms that varenicline effectively reduces nicotine self-
administration in rats (O'Connor et al. 2010; Rollema et al.
2007). Furthermore, in a rat model for relapse, varenicline
attenuated nicotine primed relapse to nicotine seeking as
well as relapse induced by a combination of a nicotine
prime and associated cues. In contrast, varenicline had no
effect on cue-induced relapse alone (O'Connor et al. 2010).
Interestingly, recent findings suggest that varenicline
may also modulate alcohol seeking and intake in heavy
drinking smokers as well as laboratory animals (McKee et
al. 2009; Steensland et al. 2007). Consistent with these
findings, varenicline was shown to counteract alcohols'
enhancing effect on dopamine levels in the nucleus
accumbens in rats (Ericson et al. 2009). Lowering dopa-
mine levels in this region has previously been associated
with reduced alcohol consumption in rats (Ericson et al.
1998, 2000; Soderpalm et al. 2000). Together, these
findings underline the potential of varenicline as a treatment
for alcohol use disorders in addition to its efficacy as a
smoking cessation aid.
In humans, abstinence and relapse are associated with
cognitive deficits (Scheurich 2005). Therefore, cognitive
enhancing agents are pursuit as pharmacotherapy targets for
addiction (Sofuoglu 2010). In this respect, nicotine receptor
(nAChR) agonists are interesting targets, since acute and
chronic administration of nAchR agonists can produce
long-lasting cognitive enhancing effects (Buccafusco et al.
2005), such as improvement of working and spatial
memory, facilitated associative learning and improved
attentional processing (Levin et al. 2006; Rezvani and
Levin 2001). For that reason, the putative cognitive
enhancing effects of varenicline warrant investigation.
In the current study, we aim to further elucidate the
motivational and cognitive effects of varenicline, with a
particular focus on the relapse-preventing properties of this
compound in an alcohol seeking and taking model. To that
end, we tested the effects of varenicline on both self-
administration and relapse to alcohol and nicotine seeking.
Moreover, to control for drug specificity, we also evaluated
the effects of varenicline on self-administration of the natural
reinforcer sucrose. Finally, we employed the 5-choice serial
reaction time task (5-CSRTT) to assess possible cognitive
enhancing effects of varenicline at the level of visuospatial
attention and inhibitory response control (Robbins 2002), the
latter being a behavioural trait associated with enhanced
motivation to initiate and maintain nicotine self-
administration in rats (Diergaarde et al. 2008).
Methods
Animals
Male Wistar rats (Harlan CPB, Horst, The Netherlands),
weighing 280–320 g upon arrival, were used. They were
housed in pairs in a temperature- and humidity-controlled
room on a 12-h light/dark cycle (lights on between 7 p.m.
and 7 a.m.), with the exception that animals that were
implanted with intravenous silicon catheters were individ-
ually housed. Catheters were implanted in the right jugular
vein under gas anaesthesia (Isoflurane) as described before
(De Vries et al. 1999). All training and testing sessions
were conducted during the dark phase of the light–dark
cycle, at the same time each day. Experimental procedures
were approved by the Animal Ethical Committee of the VU
University, Amsterdam, The Netherlands.
Apparatus and behavioural procedure
Self-administration
Self-administration training and testing was conducted in
32 identical operant chambers enclosed in sound-
attenuating ventilated cubicles (Med Associates Inc., St.
Albans, VT, USA). The operant chambers were equipped
with a grid floor, two nose poke holes and a central
reinforcer receptacle; a dim red house light and a tone
module (ENV-223AM Med Associates Inc.) were fitted on
the opposite wall. During self-administration, reinforcers
were delivered by an infusion pump (PHM-100, Med
Associates Inc.).
Animals were placed in the operant chamber, and after
30 s, the house light was switched on and trials started.
Each trial was signalled by illumination of a red stimulus
light located above the active hole, which was extinguished
when a nose poke was made into this hole. An active nose
poke resulted either in an intravenous (i.v.) infusion of
nicotine (40 μg/kg), the delivery of 0.2 ml alcohol (12%,
v/v) or 0.2 ml 10% sucrose in the receptacle, and a yellow
stimulus light in the nose poke hole was illuminated for
5 s combined with a 2-s tone signal (±68 dB, 2,900 Hz).
After delivery, a time-out period of 15 s commenced,
during which, all stimulus lights were switched off until
the next trial started. Responding during time-out was
monitored, but had no programmed consequences.
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To facilitate acquisition of operant alcohol self-administration,
rats were first trained to consume alcohol in a two-bottle free-
access paradigm. In this paradigm, upon arrival, rats were
habituated to two water bottles on their home cages. Every
otherday,oneofthebottleswasreplacedbyabottlecontaining
a gradually increasing alcohol solution (from 2% to 12%, v/v).
In three weeks, the animals reached 12%, v/v alcohol, and
training proceeded to a two-bottle limited-access paradigm, i.
e. animals were given access to the 12% solution for 1 h
daily. After 10 days of limited access, animals that consumed
over 0.35 g/kg alcohol were selected to enter the operant self-
administration phase.
5-Choice serial reaction time task
Experiments were conducted in rat operant chambers with
stainless steel grid floors (MED-NPW-5L; Med Associates
Inc.). On-line control of all operant chambers and data
collection were performed using MED-PC version IV (Med
Associates Inc.). Five sessions were scheduled per week
from Monday until Friday, one session per day.
A more detailed description of training in the 5-CSRTT
has been reported previously (van Gaalen et al. 2006). In
short, rats were trained to detect and respond to a 1-s visual
stimulus in either one of five apertures, during presentation
of the stimulus or during the 2-s limited hold period, to
obtain a food pellet (45 mg, Formula P; Research Diets
Inc., New Brunswick, NJ, USA). Each session terminated
after 100 trials or 30 min, whichever occurred first. Initially,
the duration of this stimulus was 32 s and was gradually
decreased to 1 s over sessions until animals reached stable
baseline performance (accuracy >80% correct choice and <20%
errors of omission). Incorrect, premature responses (responses
duringthe5-sinter-trialinterval(ITI))anderrorsofomissiondid
not lead to the delivery of a food pellet and resulted in a
5-s time-out period, during which, the house light was
extinguished. Responses during the time-out period
resulted in a new time-out period. Perseverative
responses, i.e. repeated responding into an aperture
following correct choice and before pellet collection,
were measured but did not have any programmed
consequences. The following behavioural measures were
recorded: (1) accuracy ((number correct trials/(correct +
incorrect trials)) 100); (2) latency of correct responses, i.e.
the mean time between stimulus onset and nose poke in the
illuminated unit; (3) premature responses, i.e. the number of
premature responses before the onset of the visual stimulus,
reflecting aspects of loss of inhibitory control (impulsivity)
and(4)perseverativeresponsesaftercorrectchoice,ameasure
of compulsive behaviour; (5) omission errors, i.e. the total
number of omitted trials during a session.
Experimental design
Self-administration
In three separate experiments, we tested the effects of
varenicline on either nicotine (exp 1), alcohol (exp 2) or
sucrose (exp 3) self- administration. Behavioural training
started 1 week after surgery (nicotine), two-bottle procedure
(alcohol) or arrival (sucrose). Initially, all animals were
trained daily in 1-h sessions on a continuous reinforcement
schedule. The fixed ratio was increased during training, up
to FR3 for the nicotine groups and FR4 for alcohol and
sucrose groups. When the levels of responding met
predefined selection criteria, the effect of a graded dose of
varenicline on self-administration was tested. Criterion
performance was defined as follows. For the nicotine
group, animals that received five or more reinforcers,
distributed over the session during the last three sessions
on a FR3 schedule, were selected for testing. In the alcohol
group, animals that self-administered over 0.35 g/kg
alcohol for three consecutive days on a FR4 schedule of
reinforcement were selected for testing. In the sucrose
group, all animals received five or more reinforcers,
distributed over the session during the last three sessions
on a FR4 schedule and were selected for testing.
Varenicline tests were conducted twice a week, on
Tuesdays and Fridays. On intermediate days, rats were
trained to self-administer nicotine, alcohol or sucrose
without being treated with varenicline. To explore the
effects of varenicline on self-administration, a within-
subject design was used, and treatment was randomized
over the subjects using a Latin square design.
To facilitate acquisition, the alcohol group (exp 2) was
given a single 20-min habituat i o ns e s s i o no nt h ef i r s t
training day, during which, only the house light was
illuminated. Nose poking during this session was without
any behavioural consequences. Furthermore, these animals
received one free sample of alcohol in the central receptacle
upon the start of the habituation session and the first five
training sessions.
Cue-induced relapse
To asses the effects of varenicline on cue-induced relapse to
nicotine or alcohol seeking, two separate groups of animals
were trained to criterion performance and subsequently
underwent extinction training. Thus, animals were placed in
the training context for 15 daily sessions of 1 h, without
audiovisual cue-exposure or reinforcer delivery.
Relapse Rats were divided into four experimental groups
that received either vehicle, 0.5, 1.5 or 2.5 mg/kg
varenicline. On the test day, all animals were injected with
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placed in the training context for a 30-min relapse test.
During the relapse test, the house light and red cue light
were turned on, and nose poking resulted in the presenta-
tion of the discrete compound audiovisual cues (but no
reinforcer delivery) on the FR schedule used during
training. In the alcohol group, 0.20 ml alcohol (12%, v/v)
was delivered in the receptacle before the session started.
We conducted a series of pilot studies investigating cue-
induced alcohol seeking under several conditions. Data
from these studies and work by others indicate that adding a
single drop of alcohol, that induces the gustatory, but not
the pharmacological effects of alcohol, results in optimal
relapse (Le and Shaham 2002).
5-Choice serial reaction time task
To assess putative cognitive enhancing effects of vareni-
cline, rats were trained in the 5-CSRTT until they reached
stable baseline performance on stimulus duration 1 s (accu-
racy>80%correctchoiceand<20%errorsofomissionduring
the last five sessions). Subsequently, the effects of varenicline
were assessed using a Latin square design, and tests were
conducted twice a week, on Tuesdays and Fridays. On
intermediate days, rats were trained normally without being
treated with varenicline. Following the tests with varenicline,
animals were trained for an additional week and tested under
increased attentional demand by reducing the stimulus
duration to 0.5 s. Subsequently, under these conditions, the
effect of 1.5 mg/kg varenicline was tested.
Drugs
Nicotine hydrogen tartrate salt (Sigma, St Louis, MO,
USA) was dissolved in sterile saline, and the pH of the
solution was adjusted to ±7.4 with diluted NaOH. The
nicotine dose is expressed as free base weight. For all
alcohol solutions used, 96% laboratory alcohol (Inter-
chema, Oosterzee, the Netherlands) was diluted with water
to reach the appropriate concentrations. Varenicline (kindly
provided by Solvay Pharmaceuticals, Weesp, the Nether-
lands) was suspended in a 1% methylcellulose–5% manni-
tol solution, and the pH was adjusted to 7.9. In all studies,
varenicline was administered intraperitoneally with an
injection volume of 2 ml/kg, 30 min before testing, and
doses were 0.5, 1.5 and 2.5 mg/kg based on previous
studies (Rollema et al. 2007; Steensland et al. 2007).
Statistical analyses
All statistical analyses were performed using the Statistical
Package for the Social Sciences version 15.0 (SPSS Inc.,
Chicago, IL, USA), and all data are displayed as mean ±
SEM. The homogeneity of variance across groups was
determined using Mauchly's tests for equal variances and in
case of violation of homogeneity, corrected Huynh–Feldt
degrees of freedom and resulting more conservative
probability values were used for subsequent analyses. In
case of statistically significant main effects, further post hoc
comparisons were conducted using Student–Newman–
Keuls tests. The level of probability for statistically
significant effects was set at 0.05.
For the self-administration data, the dependent variables
(i.e. total number of nose poke responses in the active and
inactive hole and number of reinforcers) were analyzed
using a repeated measures analysis of variance (ANOVA)
with varenicline doses as within-subject factor. For the
relapse experiments, a between-subject design was
employed; thus, the different doses of varenicline served
as between-subject factors. Data obtained in the 5-CSRTT
were subjected to repeated measures ANOVA with vareni-
cline treatment as a within-subject factor.
Results
Experiment 1: nicotine self-administration
To investigate the effects of varenicline on nicotine self-
administration, 16 rats were trained to nose-poke for
intravenous nicotine infusions in the presence of audiovi-
sual cues. Six animals were excluded because they did not
meet the selection criteria or had clogged catheters.
Varenicline treatment had an overall main effect on the
total number of active nose pokes (F(3,27)=36.04, p<
0.001), and further post hoc analyses revealed that 1.5 and
2.5 mg/kg varenicline significantly reduced nicotine self-
administration compared to vehicle (Fig. 1a). Varenicline
treatment also affected the total number of inactive
responses (F(3,27)=2.98, p<0.05). Post hoc analyses
revealed that inactive responding did not differ from vehicle
treatment for any of the varenicline doses; however, the
2.5-mg/kg dose significantly reduced the number of
inactive responses compared to 0.5 mg/kg varenicline.
Experiment 2: alcohol self-administration
In experiment 1, varenicline was able to dose-dependently
reduce nicotine self-administration. To investigate its
effects on alcohol self-administration, a separate group of
16 animals was trained. Twelve animals met our selection
criteria. Varenicline treatment had an overall main effect on
operant self-administration of alcohol (F(3,33)=7.65, p<
0.001), and post hoc analyses revealed that 1.5 and 2.5 mg/kg
varenicline significantly reduced alcohol self-administration
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varenicline treatment was also found on the total number of
inactive responses (F(3,33)=3.96, p<0.05). Post hoc analy-
ses revealed that inactive responding did not differ from
saline treatment for any of the varenicline doses; however,
both treatment with 1.5 and 2.5 mg/kg varenicline signifi-
cantly reduced the number of inactive responses compared to
treatment with 0.5 mg/kg varenicline.
Experiment 3: sucrose self-administration
To assess whether varenicline treatment selectively affects
nicotine and alcohol self-administration over responding for
natural reinforcers, eight rats were trained to nose-poke for
10% sucrose reinforcers in the presence of audiovisual
cues. All animals acquired stable self-administration of
sucrose. Varenicline had an overall main effect on operant
self-administration of sucrose (F(3,21)=6.61, p<0.01), and
post hoc analyses revealed that all varenicline doses
significantly increased sucrose self-administration com-
pared to vehicle (Fig. 1c). In addition, a main effect of
varenicline treatment was also found for the total number of
inactive responses (F(3,21)=3.49, p<0.05). Post hoc
analyses revealed that only treatment with 2.5 mg/kg
varenicline significantly reduced the number of inactive
responses compared to vehicle treatment.
Experiment 4: nicotine relapse
To assess whether varenicline would be protective against
relapse to nicotine seeking, we investigated its effects on
cue-induced relapse after extinction. Fifty-four animals met
the selection criteria and were divided into four groups
(vehicle (n=18), 0.5 mg/kg (n=12), 1.5 mg/kg (n=12) or
2.5 mg/kg (n=12) varenicline). The different experimental
groups displayed equivalent levels of active responding
during the last 2 days of training and extinction (data not
shown). Varenicline had an overall main effect on cue-
induced relapse to nicotine self-administration (F(3,50)=
4.28, p<0.01; Fig. 2a). Further comparisons revealed that
the 0.5-mg/kg dose increased responding for nicotine cues
compared to vehicle and 2.5 mg/kg (p<0.05). Treatment
with 2.5 mg/kg varenicline significantly reduced the
number of active responses compared to treatment with
0.5 mg/kg varenicline. A treatment effect was also found
for inactive responses (F(3,50)=2.98, p<0.05). Post hoc
analyses revealed an increase in inactive responding in the
0.5-mg/kg varenicline group compared to all other groups.
Experiment 5: alcohol relapse
Before the cue-induced relapse test was conducted, the
different experimental groups (vehicle (n=10), 0.5 mg/
kg (n=10), 1.5 mg/kg (n=10) or 2.5 mg/kg (n=10)
varenicline) displayed equivalent levels of active respond-
ing during the last 2 days of training and extinction (data
not shown). Varenicline had an overall main effect on
relapse to alcohol seeking (F(3,36)=13.63, p<0.001), and
post hoc analyses revealed that 1.5 and 2.5 mg/kg
varenicline significantly reduced relapse to alcohol seek-
ing compared to vehicle, whereas the 0.5 mg/kg dose
seemed to induce a slight, but non-significant increase in
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Fig. 1 Effects of varenicline on self-administration of a nicotine, b
alcohol and c sucrose (inactive responses sucrose self-administration
(mean ± SEM): 0.0 g/kg, 3±1.6; 0.5 g/kg, 1.7±0.5; 1.5 g/kg, 0.1±0.1;
2.5 g/kg, 0.1±0.1). *p<0.05 significant difference with respect to
0.0 g/kg group
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not affect inactive responding (F(3,36)=0.60, p=0.618).
Experiment 6: 5-CSRTT
To assess putative cognitive-enhancing effects of vareni-
cline, 16 rats were trained in the 5-CSRTT. Varenicline
treatment had a main effect on attention (F(3,45)=3.92, p<
0.05), premature responding (F(3,45)=3.15, p<0.05) and
correct response latency (F(3,45)=2.28, p<0.05), but not
on the number of omissions (F(3,45)=2.28, p=0.1; Fig. 3).
Post hoc analyses showed that the number of premature
responses was increased by the 0.5- and 1.5-mg/kg dose of
varenicline (p<0.05), whereas the 2.5-mg/kg dose tended to
increase the number of premature responses (p=0.06). With
regard to the effects on attention and correct response
latencies, post hoc analyses revealed no significant effects
of any dose compared to vehicle. However, 2.5 mg/kg
varenicline did increase correct response latency compared
to the 0.5- and 1.5-mg/kg dose.
To investigate whether varenicline would enhance
performance under conditions of increased attentional load,
the effect of 1.5 mg/kg varenicline was tested in combina-
tion with a reduced stimulus duration of 0.5 s. Increasing
the attentional load by reducing the stimulus duration from
1 to 0.5 s reduced accuracy (F(1,15)=36.94, p<0.001),
shortened response latencies (F(1,15)=13.62, p<0.01) and
increased omission rate (F(1,15)=69.40, p<0.001), where-
as premature responding remained unaffected (F(1,15)=
2.3, p=0.15; Fig. 4). In accordance with the aforementioned
results, 1.5 mg/kg varenicline increased the number of
premature responses (F(1,15)=27.45, p<0.001), but did not
alter accuracy (F(1,15)=1.42, p=0.25) or correct response
latencies (F(1,15)=1.65, p=0.20). A reduction of omissions
was seen after varenicline treatment (F(1,15)=15.11, p<
0.001). Furthermore, a treatment × stimulus duration
interaction effect for correct response latency was found
(F(1,15)=6.00, p<0.05). Post hoc analyses indicated that
the reduction of correct response latencies induced by
increased attentional load was less pronounced following
varenicline treatment. None of the other parameters showed
a treatment × stimulus duration interaction (accuracy, F
(1,15)<1, p=0.85; omissions, F(1,15)=1.83, p=0.20);
premature responding, F(1,15)=1.89, p=0.15).
Discussion
In the present study, we evaluated the effects ofvarenicline on
both motivational processes (nicotine, alcohol and sucrose
seeking) and cognitive functions (visuospatial attention and
inhibitory response control) in rats. We confirm earlier
observations demonstrating that varenicline attenuates nico-
tine and alcohol self-administration (O'Connor et al. 2010;
Rollema et al. 2007; Steensland et al. 2007). In contrast, self-
administration of the natural reinforcer sucrose was increased
by varenicline. Importantly, we demonstrate for the first
time that varenicline dose-dependently reduces cue-
induced relapse to alcohol seeking. Interestingly, cue-
induced relapse to nicotine seeking was not affected by
the higher doses, and the lowest dose of varenicline
(0.5 mg/kg) increased responding for nicotine-associated
cues. At the cognitive level, we show that varenicline
reduces inhibitory response control without affecting
measures of visuospatial attention in a 5-choice serial
reaction time task (5-CSRTT).
In the treatment of drug addiction, relapse after absti-
nence represents a major problem. Ideally, pharmacothera-
pies for drug addiction would aid the cessation of drug
intake and prevent relapse. As both preclinical and clinical
data indicate that varenicline may potentially posses both
characteristics (Gonzales et al. 2006; Jorenby et al. 2006;
O'Connor et al. 2010; Patterson et al. 2009; Rollema et al.
2007, 2009; Steensland et al. 2007; Tonstad et al. 2006;
Tonstad 2006), we determined the anti-relapse properties of
varenicline in a so-called self-administration–reinstatement
model (Shaham et al. 2003). Remarkably, we found that
varenicline strongly attenuated cue-induced alcohol seeking
at the same doses that reduced alcohol self-administration.
This finding suggests that varenicline has putative protec-
Fig. 2 Effects of varenicline on
cue-induced reinstatement
of a nicotine and b alcohol
seeking. *p<0.05 significant
difference with respect to
0.0 g/kg group
272 Psychopharmacology (2011) 216:267–277tive effects against relapse to alcohol use, an important
addition to the growing body of evidence that underlines
the potential of varenicline as a treatment for alcohol use
disorders.
How varenicline modulates the neurobiological mecha-
nisms that mediate cue-induced relapse to alcohol seeking
remains to be unravelled. Pharmacological studies have
identified several neurotransmitter systems that appear to be
involved in alcohol relapse, including the glutamate, opioid,
serotonin and dopamine system. In particular, activation of
the mesolimbic dopamine system and alterations in excit-
atory amino acid neurotransmission may underlie relapse to
alcohol seeking (Le and Shaham 2002). Since varenicline
was reported to affect dopamine release in the nucleus
accumbens (Coe et al. 2005; Ericson et al. 2009; Rollema et
al. 2007), it may alter relapse to alcohol seeking by
modulating dopaminergic neurotransmission in the meso-
limbic pathway.
In a separate experiment, we assessed the effects of
varenicline on cue-induced relapse to nicotine seeking.
Remarkably, we found that varenicline, at doses that
diminished relapse to alcohol seeking, did not reduce cue-
induced relapse to nicotine seeking. These results are
consistent with recent findings of O'Connor et al. (2010).
Furthermore, we found enhanced cue-induced relapse at a
dose of 0.5 mg/kg. Interestingly, a similar but non-
significant (p=0.07) effect was seen on alcohol seeking.
Thus, it seems that varenicline affects cue-induced relapse
in a bimodal fashion. A possible explanation may be that
the anti-relapse effect is mediated by receptors other than
the α4β2 nACh subtype that are activated at higher
doses, while at low doses, varenicline induces a priming
effect via α4β2 nACh receptors. Indeed, varenicline was
shown to be a (partial) agonist for other nACh receptor
subtypes, such as α7 and at higher doses α3β4, α3β2
and α6 receptors, albeit with much lower affinity (Coe et
al. 2005; Mihalak et al. 2006). Hence, varenicline may
activate additional nAch receptor subtypes at 1.5 and
2.5 mg/kg (Rollema et al. 2009).
Regarding varenicline's effects on self-administration,
our findings confirm that varenicline dose-dependently
attenuates nicotine self-administration. Substantial evidence
indicates that varenicline may affect nicotine self-
administration by reducing nicotine-induced mesolimbic
dopamine release (Coe et al. 2005; Rollema et al. 2007). In
agreement with results from Steensland et al. (2007), our
data suggest that varenicline has a comparable effect on
alcohol self-administration. Similarly, co-administration of
varenicline and alcohol counteracted each other's respective
enhancing effect on dopamine levels in the nucleus
accumbens (Ericson et al. 2009). Nonetheless, it remains
to be determined whether varenicline's attenuating effect on
alcohol and nicotine self-administration is mediated by the
same molecular mechanisms. As mentioned before, vareni-
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Psychopharmacology (2011) 216:267–277 273cline is known to have limited selectivity for different
nACh receptor subtypes (Coe et al. 2005; Mihalak et al.
2006). Some of these receptor subtypes are implicated in
the reinforcing effects of alcohol (Chastain 2006; Davis and
de Fiebre 2006; Ericson et al. 2009; Jerlhag et al. 2006;
Larsson et al. 2004; Lof et al. 2007). Particularly, the α3β4
nAch receptor seems a likely candidate for the modulation
of alcohol intake (Chatterjee et al. 2010). Therefore, we
cannot exclude the notion that varenicline differentially
mediates its effects on nicotine and alcohol self-
administration via receptors other than the α4β2 nACh
receptor.
To determine whether the attenuating effects of vareni-
cline were selective for alcohol and nicotine and/or due to a
reduced ability to make an operant response, we assed its
effects on operant responding for the natural reinforcer
sucrose. Interestingly, sucrose self-administration was aug-
mented by varenicline at doses that significantly reduced
nicotine and alcohol self-administration. Previous studies
investigating intake of natural reinforcers have not reported
such effects (O'Connor et al. 2010; Steensland et al. 2007).
Varenicline was however reported to increase responding
for food delivery in rats trained on a variable interval
reinforcement schedule (Rollema et al. 2007). A role for
nACh receptors in sucrose seeking, however, is not
supported by previous data, i.e. nACh receptor agonists
and antagonists have not been reported to attenuate sucrose
intake (Ford et al. 2009; Hendrickson et al. 2009; Nadal et
al. 1998; Neugebauer et al. 2006; Steensland et al. 2007).
Collectively, these findings imply the following. First,
that varenicline selectively attenuates self-administration of
alcohol and nicotine, an effect that does not generalize to
self-administration of food or sucrose. In fact, our findings
suggest that varenicline affects operant responding for
natural reinforcers and addictive substances, i.e. nicotine
and alcohol, in opposite directions. Second, as varenicline
treatment did not impair sucrose self-administration, vare-
nicline's effects on consumption of addictive substances are
most probably due to changes in the motivational domain,
rather than impaired abilities to perform an operant
response.
In humans, varenicline was shown to enhance cognitive
functioning during abstinence of smoking/drinking. Although
the effects were small, varenicline improved sustained
attention (as measured by the Penn Continuous Performance
Task) and working memory (as measured by the letter N-back
task; Patterson et al. 2009). Furthermore, recent rodent
studies show that varenicline may ameliorate alcohol-
induced cognitive deficits in acquisition of contextual and
cued associative learning in mice (Gulick and Gould 2008)
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274 Psychopharmacology (2011) 216:267–277and improve attentional performance in a sustained attention
task with distractor stimuli in rats (Rollema et al. 2009). We
used the 5-choice serial reaction time task (5-CSRTT) to
further explore the effects of varenicline on cognition.
Previous research from our and other laboratories revealed
that nicotine positively affects cognitive function as mea-
sured in the 5-CSRTT by (1) enhancing sustained attention
under certain conditions, (2) decreasing response latency and
(3) reducing the number of omissions. On the other hand,
nicotine deteriorates inhibitory control in this task as
measured by an increase in premature responding (Blondel
et al. 2000; Day et al. 2007; Mirza and Stolerman 1998;v a n
Gaalen et al. 2006). In the current study, we found no
evidence for cognitive-enhancing effects of varenicline.
However, varenicline increased premature responding, albeit
to a lesser extent than nicotine (Blondel et al. 2000;M i r z a
and Stolerman 1998; van Gaalen et al. 2006). This effect
may result from enhanced dopaminergic neurotransmis-
sion in the mesolimbic pathway induced by nACh
receptor activation in the nucleus accumbens or ventral
tegmental area (Di Chiara and Imperato 1988; Marshall et
al. 1997;N i s e l le ta l .1994; Wonnacott 1997), that in turn
has been demonstrated to modulate premature responding
in the 5-CSRTT (Cole and Robbins 1987;P a t t i je ta l .
2007). It should be noted here that detrimental effects of
varenicline on inhibitory response control may be unfav-
ourable during treatment in humans, as previous research
from our laboratory has associated poor inhibitory response
control with an enhanced motivation to initiate and maintain
nicotine self-administration in rats (Diergaarde et al. 2008).
Likewise,inlinewiththesepreclinicalfindings,diminished
inhibitory control has been demonstrated to predict unsuc-
cessful smoking cessation in abstinent smokers (Krishnan-
Sarin et al. 2007). Interestingly, recent findings from our
laboratory suggest that under comparable conditions, no
such association exists between inhibitory response control
and alcohol self-administration in rats (Diergaarde, unpub-
lished). The strong relationship between impulsivity and
nicotine, but not alcohol seeking, together with the
observation that varenicline diminishes inhibitory control
may partly explain the differential effects of this
compound on relapse to alcohol and nicotine seeking.
We also tested varenicline in combination with a reduced
stimulus duration (0.5 s instead of 1 s) to assess its effects
on performance under increased attentional load. Compared
to saline treatment, varenicline was unable to improve
attentional performance under these challenging conditions.
This seems to contradict previous data demonstrating that
varenicline significantly improved the capacity to attenuate
impaired performance under challenging distractor condi-
tions in a sustained attention task (Rollema et al. 2009).
Specific differences between the 5-CSRTT and the sus-
tained attention task may explain this discrepancy. In
particular, in the sustained attention task, an auditory
stimulus was used to reduce the discriminability of a visual
cue, whereas in the 5-CSRTT, the signal duration of a
visual cue was reduced. It is possible that varenicline
reduces the impact of a distractor on signal detection, but
does not improve sustained attention. Taken together,
varenicline's effects on cognitive functions as measured in
the 5-CSRTT seem limited and less pronounced than the
effects of nicotine, consistent with its lower efficacy at the
nACh receptor.
In summary, this is the first report to demonstrate that, in
rats, varenicline attenuates cue-induced alcohol seeking.
Furthermore, at lower doses, varenicline may facilitate
nicotine seeking. As was previously shown, varenicline
may selectively reduce voluntary nicotine and alcohol
intake. Moreover, varenicline has limited effects on
cognitive functioning as measured by the 5-CSRTT,
although varenicline may somewhat reduce inhibitory
response control. Such a behavioural pharmacological
profile emphasizes varenicline's potential as a pharmaco-
therapeutical agent in the treatment of alcohol dependence.
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